Mizuho believes Harmony Biosciences (HRMY)’ near-term growth is “now a bigger question” after the company announced a negative Phase 3 result for ZYN002 in fragile X syndrome, citing a higher than expected placebo response. The company is not hosting a conference call to discuss the data, the analyst tells investors in a research note. Harmony in premarket trading is down 6% to $30.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Morning Movers: uniQure skyrockets after AMT-130 trial meets primary endpoint
- Harmony Biosciences Stock (HRMY) Sinks on Failed Phase 3 Study
- Harmony Biosciences announces RECONNECT study did not meet primary endpoint
- Harmony Biosciences price target lowered to $48 from $49 at Needham
- Harmony Biosciences: Buy Rating Affirmed on Strong Growth Prospects and Strategic Advancements